The non-steroidal MRA finerenone in cardiorenal medicine: a state-of-the-art review of the literature.
Sign Up to like & getrecommendations! Published in 2022 at "American journal of hypertension"
DOI: 10.1093/ajh/hpac124
Abstract: Steroidal mineralocorticoid-receptor-antagonists (MRAs), such as spironolactone and eplerenone, are guideline-directed therapies in patients with heart failure with reduced ejection fraction or resistant hypertension. However, the associated risk of hyperkalemia and hormonal side effects limit their… read more here.
Keywords: steroidal mra; finerenone; risk; non steroidal ... See more keywords